Eton Historical Financial Ratios
| ETON Stock | USD 13.02 0.49 3.63% |
Eton Pharmaceuticals is recently reporting on over 114 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 14.83 or Days Sales Outstanding of 47.65 will help investors to properly organize and evaluate Eton Pharmaceuticals financial condition quickly.
Eton |
About Eton Financial Ratios Analysis
Eton PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Eton Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Eton financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Eton Pharmaceuticals history.
Eton Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Eton Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Eton Pharmaceuticals sales, a figure that is much harder to manipulate than other Eton Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Eton Pharmaceuticals dividend as a percentage of Eton Pharmaceuticals stock price. Eton Pharmaceuticals dividend yield is a measure of Eton Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Eton Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Eton Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Eton Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.At this time, Eton Pharmaceuticals' Days Of Inventory On Hand is very stable compared to the past year. As of the 28th of March 2025, Payables Turnover is likely to grow to 3.93, while Price To Sales Ratio is likely to drop 8.40.
| 2024 | 2025 (projected) | Dividend Yield | 0.024 | 0.0214 | Price To Sales Ratio | 8.84 | 8.4 |
Eton Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Eton Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eton Pharmaceuticals fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 4.4K | 4.95 | 3.34 | 3.55 | 8.84 | 8.4 | |
| Ptb Ratio | 10.91 | 6.13 | 5.42 | 7.26 | 14.12 | 14.83 | |
| Days Sales Outstanding | 449.23 | 91.47 | 31.81 | 39.35 | 50.16 | 47.65 | |
| Book Value Per Share | 0.75 | 0.7 | 0.52 | 0.6 | 0.94 | 1.22 | |
| Free Cash Flow Yield | (0.13) | (0.0738) | 0.0287 | 0.0538 | 0.002734 | 0.002871 | |
| Operating Cash Flow Per Share | (1.06) | (0.19) | 0.19 | 0.27 | 0.0374 | 0.0393 | |
| Stock Based Compensation To Revenue | 66.05 | 0.15 | 0.2 | 0.0991 | 0.0811 | 0.0771 | |
| Capex To Depreciation | 0.0768 | 7.05 | 1.57 | 0.86 | 0.0227 | 0.0216 | |
| Pb Ratio | 10.91 | 6.13 | 5.42 | 7.26 | 14.12 | 14.83 | |
| Ev To Sales | 4.0K | 4.6 | 2.88 | 3.04 | 8.46 | 8.04 | |
| Free Cash Flow Per Share | (1.07) | (0.32) | 0.0808 | 0.24 | 0.0364 | 0.0382 | |
| Roic | (1.23) | (0.0931) | (0.46) | (0.0776) | (0.0464) | (0.0487) | |
| Inventory Turnover | 0.23 | 4.77 | 12.45 | 11.61 | 1.02 | 0.97 | |
| Net Income Per Share | (1.37) | (0.12) | (0.39) | (0.0365) | (0.15) | (0.16) | |
| Days Of Inventory On Hand | 1.6K | 76.53 | 29.32 | 31.43 | 356.39 | 437.24 | |
| Payables Turnover | 0.79 | 0.12 | 1.48 | 3.93 | 5.73 | 3.74 | |
| Sales General And Administrative To Revenue | 327.18 | 0.66 | 0.87 | 0.6 | 0.58 | 0.55 | |
| Research And Ddevelopement To Revenue | 361.64 | 0.29 | 0.19 | 0.1 | 0.0834 | 0.0793 | |
| Capex To Revenue | 1.28 | 0.15 | 0.13 | 0.0245 | 6.66E-4 | 6.33E-4 | |
| Cash Per Share | 1.01 | 0.57 | 0.65 | 0.83 | 0.58 | 0.55 | |
| Pocfratio | (7.64) | (22.91) | 14.71 | 16.48 | 355.96 | 373.75 | |
| Capex To Operating Cash Flow | (0.002238) | (0.69) | 0.58 | 0.11 | 0.0268 | 0.0282 | |
| Pfcf Ratio | (7.63) | (13.55) | 34.88 | 18.6 | 365.77 | 384.06 | |
| Days Payables Outstanding | 3.0K | 246.86 | 92.97 | 63.75 | 97.5 | 92.62 | |
| Income Quality | 0.8 | 2.41 | (0.53) | (7.28) | (0.25) | (0.27) | |
| Roe | (1.71) | (1.84) | (0.17) | (0.75) | (0.0605) | (0.16) | |
| Ev To Operating Cash Flow | (7.01) | (21.27) | 12.68 | 14.14 | 340.65 | 357.69 | |
| Pe Ratio | (5.92) | (36.52) | (7.25) | (120.01) | (90.22) | (85.71) | |
| Return On Tangible Assets | (1.12) | (0.12) | (0.48) | (0.0347) | (0.0927) | (0.0973) | |
| Ev To Free Cash Flow | (6.99) | (12.58) | 30.07 | 15.95 | 350.04 | 367.55 | |
| Earnings Yield | (0.14) | (0.17) | (0.0274) | (0.008333) | (0.0111) | (0.0116) | |
| Intangibles To Total Assets | 0.0218 | 0.13 | 0.19 | 0.15 | 0.46 | 0.48 | |
| Net Debt To E B I T D A | 0.53 | 6.88 | 1.51 | 54.93 | 5.71 | 7.44 | |
| Current Ratio | 6.51 | 5.18 | 3.1 | 1.65 | 2.06 | 1.95 | |
| Tangible Book Value Per Share | 0.72 | 0.56 | 0.33 | 0.42 | (0.4) | (0.38) | |
| Receivables Turnover | 0.81 | 3.99 | 11.47 | 9.28 | 7.28 | 4.65 | |
| Shareholders Equity Per Share | 0.75 | 0.7 | 0.52 | 0.6 | 0.94 | 1.22 | |
| Debt To Equity | 0.46 | 0.38 | 0.5 | 0.35 | 0.00438 | 0.004161 | |
| Capex Per Share | 0.00238 | 0.13 | 0.11 | 0.0302 | 0.001004 | 9.54E-4 |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.65 | INBX | Inhibrx Symbol Change | PairCorr |
| 0.52 | VINC | Vincerx Pharma | PairCorr |
| 0.43 | ZURA | Zura Bio Limited | PairCorr |
| 0.41 | MRK | Merck Company | PairCorr |
| 0.38 | ELVN | Enliven Therapeutics | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.